Several analysts have recently updated their ratings and price targets for GlycoMimetics (NASDAQ: GLYC):

  • 10/23/2017 – GlycoMimetics is now covered by analysts at Roth Capital. They set a “buy” rating and a $25.00 price target on the stock.
  • 10/16/2017 – GlycoMimetics was downgraded by analysts at Zacks Investment Research from a “strong-buy” rating to a “hold” rating. According to Zacks, “GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. “
  • 10/6/2017 – GlycoMimetics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States. “
  • 10/4/2017 – GlycoMimetics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $21.00 price target on the stock.
  • 9/1/2017 – GlycoMimetics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

GlycoMimetics, Inc. (NASDAQ GLYC) opened at 10.76 on Tuesday. The firm has a 50 day moving average of $12.56 and a 200-day moving average of $10.40. The stock’s market cap is $352.10 million. GlycoMimetics, Inc. has a 52-week low of $3.82 and a 52-week high of $16.94.

GlycoMimetics (NASDAQ:GLYC) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.07. Equities analysts anticipate that GlycoMimetics, Inc. will post ($1.22) earnings per share for the current fiscal year.

In other news, SVP Helen M. Thackray sold 2,000 shares of the stock in a transaction on Monday, September 18th. The shares were sold at an average price of $13.00, for a total value of $26,000.00. Following the sale, the senior vice president now owns 150,615 shares of the company’s stock, valued at $1,957,995. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 43.80% of the company’s stock.

GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.

Receive News & Ratings for GlycoMimetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.